Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By



Executive Summary

Combined worldwide sales of Syntex' Naprosyn (naproxen) and Anaprox (naproxen sodium) jumped 19.4% to $205.2 mil. in the fourth quarter (ended July 31). Sales from the two NSAIDs were up 8% for the fiscal year at $802.5 mil. In the last three months, U.S. sales of Naprosyn and Anaprox jumped 22.1% to $148.4 mil. Naprosyn's share of new prescriptions hit 18.2% in the quarter, a turnaround from a low of 16% in March 1989. Non-U.S. fourth quarter sales rose 12.9%. to $56.8 mil. New products generated approximately $40 mil. in sales and accounted for 45% of the increase in human pharmaceutical sales in the fourth quarter, Syntex said. For the year, revenues from Toradol, Synarel, Cytovene and Cardene totaled approximately $105 mil. Syntex worldwide human pharmaceutical sales climbed 26.6% to $336.5 mil. for the quarter and 13.1% at $1.271 bil. for the year. Corporate revenues rose 13% for the year to $1.5 bil. Net income jumped 49% in the quarter to $75.1 mil., and was 12.6% higher for the year at $341.5 mil.



Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts